Managing breakthrough pain

Abstract

Get full access to this article

View all access options for this article.

References

Cleary JF : Pharmacokinetic and pharmacodynamic issues in the treatment of breakthrough pain. Seminars in Oncology. 1997; 24(S): S13-S19.

Pappagallo M , Dickerson ED , Hulka S : Palliative care and hospice opioid dosing guidelines with breakthrough pain (BP) doses. American Journal of Hospice & Palliative Care. November/December 2000; 17(6): 407-413.

Farrar JT , Cleary J , Rauck R , et al. : Oral transmucosal fentanyl citrate: Randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. Journal of the National Cancer Institute. 1998; 90: 611-616.

Christie JM , Simmonds M , Patt R , et al. : Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. Journal of Clinical Oncology. 1998; 16: 3238-3245.